What are the uses of Pulmoclear (acebrophylline and N‑acetylcysteine)?

Pulmoclear (Acebrophylline + N-Acetylcysteine) Uses

Pulmoclear is indicated as add-on therapy for patients with moderate to severe COPD or asthma who continue to experience exacerbations despite optimal inhaled bronchodilator and corticosteroid therapy, with evidence showing improvements in lung function (FEV1) and quality of life. 1

Primary Clinical Indications

COPD Management

• For patients with moderate to severe COPD and ≥2 exacerbations in the previous 2 years, the N-acetylcysteine component (typically 600 mg twice daily) reduces annual exacerbation rates by 22% (RR 0.78) and decreases hospitalizations from 18.1% to 14.1% (NNT = 25). 2, 3
• The American College of Chest Physicians recommends N-acetylcysteine specifically for stable outpatients with moderate to severe COPD (FEV1 30-79% predicted) who remain symptomatic despite maximal inhaled therapy. 2, 3
• The combination of N-acetylcysteine and acebrophylline in Pulmoclear demonstrated significant FEV1 improvement in COPD patients (1.237 L to 1.414 L, p = 0.001) and improved CAT scores from 17.2 to 10.6 (p = 0.0001) over 90 days. 1

Asthma Management

• In moderate to severe asthma patients, the Pulmoclear combination improved FEV1 from 1.477 L to 1.747 L (p = 0.004) when used as add-on therapy for 90 days. 1
• The combination showed favorable safety and tolerability with no severe adverse events reported in clinical studies. 1

Mechanism of Action

N-Acetylcysteine Component

• Reduces viscosity of respiratory secretions through cleavage of disulfide bonds in mucoproteins, making thick secretions easier to clear from the tracheobronchial tree. 3
• Provides antioxidant effects by serving as a precursor for glutathione synthesis and directly scavenging reactive oxygen species. 3, 4
• Exhibits anti-inflammatory properties by inhibiting the ROS/CREB/ERK signaling pathway, reducing mucus hypersecretion and airway inflammation. 4

Acebrophylline Component

• Acts as a bronchodilator with mucolytic and anti-inflammatory properties, complementing the effects of N-acetylcysteine. 1

FDA-Approved Uses for N-Acetylcysteine (Component)

The N-acetylcysteine component is FDA-approved as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in: 5

• Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis)
• Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis)
• Pulmonary complications of cystic fibrosis
• Tracheostomy care and post-surgical pulmonary complications

Dosing and Duration

• The standard regimen for chronic prevention is N-acetylcysteine 600 mg twice daily orally, with benefits requiring at least 6 months of continuous therapy to become significant and optimal effects seen after 1-3 years. 3, 6
• High-dose therapy (≥1200 mg daily total) demonstrates superior efficacy compared to lower doses (rate ratio 0.69 vs 0.87). 3
• The European Respiratory Society recommends continuing mucolytic therapy long-term (1-3 years) as benefits accumulate over time. 3

Patient Selection Criteria

Target patients who meet ALL of the following: 2, 3, 6

• Moderate to severe COPD (FEV1 30-79% predicted or GOLD II-III) OR moderate to severe asthma
• History of ≥2 exacerbations in the previous year or 2 years
• Already on optimal inhaled bronchodilator therapy ± inhaled corticosteroids
• Continue to experience breakthrough exacerbations despite maximal inhaled therapy

Important Clinical Caveats

• Do NOT use N-acetylcysteine during acute exacerbations of COPD or asthma—it is indicated only for chronic prevention, not acute treatment. 3 For acute exacerbations, use short-acting β-agonists or anticholinergic bronchodilators (Grade A) and systemic corticosteroids for 10-15 days (Grade A). 3
• N-acetylcysteine appears more effective in moderate COPD (GOLD II) compared to severe disease (GOLD III), with longer time to first exacerbation in the moderate group. 3, 6
• While the combination reduces exacerbations and improves lung function, it has not been shown to significantly impact mortality in respiratory disease. 3, 6
• The benefit may be reduced in patients already using inhaled corticosteroids, as mucolytics may reduce exacerbations primarily in those not receiving ICS. 3

Safety Profile

• N-acetylcysteine is well-tolerated with rare adverse gastrointestinal effects (nausea, vomiting, diarrhea) even with prolonged use. 3, 6
• The Pulmoclear combination showed no severe adverse events in clinical trials. 1
• Low toxicity profile even when combined with other respiratory treatments. 3, 6
• No specific dose adjustment required for age alone, though renal function should be monitored in older adults. 6